Filtered By:
Specialty: International Medicine & Public Health
Drug: Coumadin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 58 results found since Jan 2013.
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
Traditionally, warfarin has been used to prevent stroke in patients with atrial fibrillation (AF), but data from large, multinational, prospective, randomized studies suggest that novel oral anticoagulants (NOACs) may be suitable alternatives. These include the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. These data showed that dabigatran 150 mg twice daily was more effective at preventing stroke than warfarin, with similar rates of major bleeding, while rivaroxaban 20 mg once daily was noninferior to warfarin, with no difference in major bleeding rates. In addition...
Source: International Archives of Medicine - October 31, 2013 Category: Global & Universal Authors: Bruce Stambler Source Type: research
Study On Drug Utilization And Assessment Of Stroke Risk Using Chads2 And Cha2ds2-Vasc Scoring In Elderly Patients With Non-Valvular Atrial Fibrillation
Stroke Risk Stratification in AF patients of can be done using CHADS2 (Congestive heart failure, Hypertension, Age ≥75, DM, prior Stroke/TIA [2 points] ); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection fraction ≤35%, Hypertension, Age ≥75 [2 points], DM, prior Stroke/TIA/thromboembolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets (Aspirin and Clopidogrel).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: T. Raj, S. Bonthu, S.R. Mallayasamy Source Type: research
Estimating the cost-effectiveness of left Atrial Appendage closure compared to warfarin for stroke prevention in Atrial Fibrillation
The objective of this study was to evaluate the cost-effectiveness of LAA closure relative to chronic warfarin therapy for stroke prevention in AF patients at elevated stroke risk.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: V. Shih, B. Devine Source Type: research
Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients
Stroke is the most severe and debilitating consequence of atrial fibrillation (AF), with many patients ranking the resultant disability as worse than death. Warfarin, the established first-line therapy, is effective at reducing ischemic stroke, but is associated with increased bleeding risk and lower quality of life (QoL). Left atrial appendage closure (LAAC) with the Watchman Device has been found to be superior to warfarin at reducing risk of stroke in AF patients. This analysis sought to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in non-valvular AF from the perspective of the US Centers ...
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: V. Reddy, R. Akehurst, S.L. Amorosi, S. Armstrong, S. Beard, C. Knight, C. Taggart, D. Holmes Source Type: research
Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
Conclusions:Novel oral anticoagulants (NOACs) seem to be a better choice as a pharmacological therapy in the treatment of AF, due to a lack of adequate monitoring of patients ’ international normalized ratio (INR) values. CHA2DS2‑VASc and HASBLED scores must be used as a part of routine clinical diagnostics when dealing with patients with AF.Keywords:Atrial fbrillation, hemorrhage, risk, stroke, therapeutics
Source: International Journal of Preventive Medicine - June 3, 2019 Category: International Medicine & Public Health Source Type: research
Medicare beneficiary out-of-pocket spending for stroke prevention in non-valvular Atrial Fibrillation: a budget analysis
Healthcare costs today are increasingly being shifted from payers to patients, yet few providers factor patient costs into treatment decisions. Recent advancements in stroke prevention in atrial fibrillation (AF) have resulted in new treatment options where previously there were few. While the clinical benefit and cost effectiveness of these treatments are supported by a growing body of evidence, the cost impact to patients has not been explored. This analysis sought to quantify patient out-of-pocket costs for three stroke prevention strategies: warfarin, dabigatran and left atrial appendage closure (LAAC) with the Watchman Device.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: S. Armstrong, S.L. Amorosi, G. Erickson, P. Patel, K. Stein Source Type: research
Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives
Conclusions Dabigatran use improves patient survival and quality of life compared with warfarin. This represents the best therapeutic option in terms of cost and effectiveness in the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Source: Value in Health Regional Issues - June 10, 2015 Category: Global & Universal Source Type: research
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research
CO55 Efficacy and Safety of Direct Oral Anticoagulants (DOACS) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: A Systematic Review and Meta-Analysis
The purpose of this meta-analysis was to compare efficacy and safety of direct oral anticoagulants (DOACs) to warfarin for secondary stroke prevention among adult patients with atrial fibrillation and prior stroke.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: K Umashankar, M Mammi, E Badawoud, Y Tang, M Zhou, JC Borges, A Liew, M Migliore, RA Mekary Source Type: research
EE340 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation in a Developing Country
This study assessed the cost-effectiveness of DOACs compared to warfarin with varying anticoagulation controls for stroke prevention in NVAF patients in real-world setting in Thailand.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M.S. Syeed, T. Nonthasawadsri, R.E. Nelson, N. Chaiyakunapruk, S. Nathisuwan Source Type: research
Setting up the Right Scenarios for Cost-Effectiveness Analysis: An Example with Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients in China
Warfarin, the standard oral anticoagulant for stroke prevention in patients with atrial fibrillation (AF), is associated with frequent international normalized ratio (INR) monitoring and increased hemorrhagic risk. About 50% of European and American AF patients received warfarin nevertheless. Dabigatran, a novel oral anticoagulant, had been compared to warfarin to demonstrate its cost-effectiveness in developed countries. However, these economic evaluations couldn’t be applied to China setting. Despite treatment guidelines, warfarin use was conservative in China accounting for only 2.7% AF patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: Y. Wan, Z.G. Lu, F. Chen, J. Chen Source Type: research
Build Model with Asia Pacific Region in Mind: Modeling INR Control in a Cost-Effectiveness Model for Stroke Prevention in Atrial Fibrillation Patients
Patients, physician behaviors, and health systems differ across regions. Models without features to account for heterogeneity can’t be readily adapted in AP region. Warfarin, the standard care for stroke prevention in atrial fibrillation patients, requires routine monitoring of International Normalized Ratio (INR). Below or above the target range (2.0-3.0) increases ischemic or hemorrhagic events, respectively. Time in therapeutic range (TTR) determines therapeutic effectiveness. INR monitoring and increased hemorrhagic risk created barriers for broad effective warfarin use in AP region.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J. Chen, Y. Wan, F. Chen, Z.G. Lu Tags: Research on Methods - Modeling Methods Source Type: research
Economic Evaluation Of Dabigatran Etexilate Versus Warfarin, Rivaroxaban And Apixaban In Stroke Prevention In Atrial Fibrilation
To determine the economic value of dabigatran for stroke prevention in atrial fibrillation (SPAF) compared to other reimbursed oral anticoagulants warfarin, rivaroxaban and apixaban from a perspective of Mexican public institutions.
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: J.L. Huicochea-Bartelt, J. Gay-Molina, L.A. Ortiz-Blas, S. Herran Source Type: research
Cost-Effectiveness Of Edoxaban Compared With Warfarin For The Prevention Of Stroke And Systemic Embolic Events In The Uk
This evaluation aimed to assess the cost-effectiveness of edoxaban 60mg versus warfarin for the prevention of stroke and systemic embolic events among patients with non-valvular atrial fibrillation (NVAF) in the UK, from the perspective of the NHS.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Taylor, L Claxton, L Lewis, AE Harrington, AF Alexandre, A Bakhai, B Brueggenjuergen Source Type: research
Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research
